PMP22 and Charcot-Marie-Tooth disease type 1A: Instead of binding to mRNA, TFOs were designed to bind to purine-rich target sequences of the two Pmp22 gene promoters within the duplex major groove to competitively inhibit the binding of transcription factors, proving useful reagents for the therapy of CMT1A [105,106].